期刊文献+

卵巢癌患者CA125水平对细胞免疫功能的影响

Effect of CA125 on the Cellular Immune Function in Patients with Ovarian Cancer
下载PDF
导出
摘要 目的体外检测卵巢癌患者血中CA125对细胞免疫功能的影响。方法收集2012年5月至2013年6月北京协和医院符合诊断标准的卵巢癌患者58例,按CA125浓度分为3组;同时收集良性妇科疾病患者20例及体检正常的健康者20名作为对照。应用细胞培养、酶联免疫吸附法、酶联免疫斑点(enzyme-linked immunospot,ELISPOT)等实验,观察体外刺激健康人淋巴细胞产生γ-干扰素(interferon-γ,IFN-γ)的能力,判断CA125对机体细胞免疫状态的影响。结果在卵巢癌患者中,随CA125水平升高,淋巴细胞绝对值及百分比值呈逐渐下降趋势。高浓度CA125卵巢癌患者的血清与植物血凝素共同刺激健康者混合淋巴细胞后,培养上清液中IFN-γ的含量[(36.16±16.89)ng/ml]较阳性对照组和低浓度CA125组[分别为(45.68±18.01)和(46.22±19.30)ng/ml]显著降低(P<0.05);ELISPOT结果显示高浓度和中浓度CA125(斑点数均值分别为108.2和371.6)对细胞免疫抑制功能与健康对照组和良性疾病组(斑点数均值分别为573.0和523.0)比较,差异均有统计学意义(P<0.01,P<0.05);而去除血清中CA125后,对细胞免疫抑制作用明显减弱。结论卵巢癌患者体内的CA125水平与淋巴细胞的数量、活性及其产生细胞因子的活性呈负相关关系。CA125除作为与卵巢癌相关的标志物外,还可能是一种细胞免疫抑制因子。 Objective To detect the effects of CA125 on cellular immune function of the ovarian cancer( OC) patients in vitro. Methods Totally 58 patients with confirmed OC in our hospital from May 2012 to June2013 were divided into three groups based on the CA125 levels. Meanwhile,20 healthy subjects( control group)and 20 patients with benign gynecological diseases( benign diseases group) were also included. The in vitro ability of healthy human lymphocytes in secreting interferon-γ( IFN-γ) under the stimulation of phytohemagglutinin( PHA) was observed by cell culture,enzyme-linked immunosorbent assay( ELISA) and enzyme-linked immunospot( ELISPOT). Results In OC patients,the count and percentage of lymphocytes decreased gradually with elevated levels of CA125. The concentration of IFN-γ in the supernatant of cultured lymphocytes from healthy individuals decreased significantly under the stimulation of PHA and high concentration of CA125 [( 36. 16 ±16. 89) ng /ml] compared with that of PHA alone [( 45. 68 ± 18. 01) ng /ml]or PHA and low concentration ofCA125 [( 46. 22 ± 19. 30) ng /ml]( both P〈0. 05). Compared with the control group( spots number 573. 0)and the benign diseases group( spots number 523. 0),the high( spots number 108. 2) and intermediate( spots number 371. 6) concentration of CA125 had significant inhibitory effect on the cellular immune system,as detected by ELISPOT( P〈0. 01,P〈0. 05,respectively). After removal of CA125 from the serum by antibody,the inhibitory effect was weakened significantly. Conclusions The concentration of CA125 in OC patient is negatively correlated with the number and activity of lymphocytes,in particular their abilities in releasing cytokines.CA125 is not only a biomarker of OC but also may serve as an immunosuppressive factor.
出处 《协和医学杂志》 2014年第3期273-277,共5页 Medical Journal of Peking Union Medical College Hospital
关键词 CA125 卵巢癌 淋巴细胞 细胞因子 Γ-干扰素 CA125 ovarian cancer lymphocyte cytokine interferon-γ
  • 相关文献

参考文献12

  • 1Kobayashi E,Ueda Y,Matsuzaki S,et al.Biomarkers for screening,diagnosis,and monitoring of ovarian cancer[J].Cancer Epidemiol Biomarkers Prev,2012,21:1902-1912.
  • 2Rooth C.Ovarian cancer:risk factors,treatment and management[J].Br J Nurs,2013,22:S23-S30.
  • 3Yin BW,Lloyd KO.Molecular cloning of the CA125 ovarian cancer antigen:identification as a new mucin,MUC16[J].J Biol Chem,2001,276:27371-27375.
  • 4Gubbels JA,Felder M,Horibata S,et al.MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells[J].Mol Cancer,2010,9:11.
  • 5Belisle JA,Gubbels JA,Raphael CA,et al.Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16(CA125)[J].Immunology,2007,122:418-429.
  • 6Patankar MS,Jing Y,Morrison JC,et al.Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125[J].Gynecol Oncol,2005,99:704-713.
  • 7Lanier LL.Natural killer cell receptor signaling[J].Curr Opin Immunol,2003,15:308-314.
  • 8Tyler C,Kapur A,Felder M,et al.The mucin MUC16(CA125)binds to NK cells and monocytes from peripheral blood of women with healthy pregnancy and preeclampsia[J].Am J Reprod Immunol,2012,68:28-37.
  • 9Radka S,Weston BS,Kieran W,et al.Exploring the glycosylation of serum CA125[J].Int J Mol Sci,2013,14:15636-15654.
  • 10朱兰(综述),郎景和(审校).肿瘤标记物在妇科领域中的应用[J].中国实验诊断学,2002,6(5):301-302. 被引量:10

二级参考文献14

  • 1[1]Ron IG, Inbar M, Gelernter Ⅰ,et al. Use of CA125 response to predict survival parameters of patients with advanced ovarian carcinoma[J]. Acta Obstet Gynecol Scand, 1994, 73:658.
  • 2[2]Fures R, Bukovic D, Hodek B, et al. Preoperative tumor marker CA125 leves in relation to epithelial ovarian cancer stage[J]. Coll Antropol, 1999, 23:189.
  • 3[3]Meier W, Baumgartmer L, Stieber P, et al. CA125 based diagnosis and therapy in recurrent ovarian cancer[J]. Anticancer Res, 1997, 17:3010.
  • 4[4]Rustin GJS, Nelstrop AE, Mcclean P, et al. Defing response of ovarian carcinoma to initail chemotherapy according to serum CA125[J]. J Clin Oncol, 1996, 14:1545.
  • 5[5]Robert PW, Mark RC, Fengji X, et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses[J]. Gynecol Oncol, 1995,59::111.
  • 6[6]Elvira M, Johannes MGB, Rob AV, et al. CA125, a vavid marker in ovarian carcinoma patients treated with paclitaxal[J]. Cancer, 1996, 78:118.
  • 7[7]Mogensen O. Prognostic value of CA125 in advanced ovarian cancer[J]. Gynecol Oncol, 1992, 44:207.
  • 8[8]Peters-Eng1 C, Buxhaum P, Ogris E, et al. TATI and cancer antigen 125(CA125) in patients with early-stage endometrial cancer[J]. Anticancer Res, 1998, 18:4635.
  • 9[9]Ozaksit G, Caglar T, Cicek N, et al. Serum CA125 levels before, during and after treatment for EM[J]. J Gynecol Obstet, 1995,50:269.
  • 10[10]Tamakoshi K, et al. CA125, CA199, CEA, CA72-4[H].Gynecol Oncol, 1996, 62:67.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部